Lunai Bioworks (LNAI) Gross Margin (2013 - 2026)

Lunai Bioworks (LNAI) posted quarterly Gross Margin of 100.0% for Q1 2026, up 14.55% quarter-over-quarter from 87.3% in Q2 2016.

Lunai Bioworks (LNAI) Gross Margin (2013 - 2026) Analysis & Trends

Lunai Bioworks' Gross Margin history runs 3 years deep, the most recent figure standing at 100.0% for Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 100.0%; the TTM figure through Mar 2026 stood at 528.92% (changed N/A YoY), while the FY2016 annual figure was 87.67%, changed N/A from the prior year.
Gross Margin for Q1 2026 stood at 100.0%, up from 87.3% in the prior quarter.
The five-year high for Gross Margin was 100.0% in Q1 2026, with the low at 100.0% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	100.00%

Download Data